Insulet (PODD) appears well-positioned on solid prospects in the diabetes market. The company is progressing well with respect to product innovation and geographic expansion. The stock carries a Zacks Rank #2 (Buy) currently.Insulet is witnessing continued uptake of Omnipod through the U.S. pharmacy channel. Insulet continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign in the United States and across select international markets. Omnipod is specifically desig ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Score ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the following appointments to the Company’s Board of Directors, effective January 18: Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories Timothy Stonesifer, Chief Financial Officer at Alcon Inc. In addition, the Company announced Shacey Petrovic and ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Inves ...

Financial Data and Key Metrics Changes - The company reported total Omnipod growth of over 27%, including US growth of 35%, and total company growth of 25% in Q3 [108] - Adjusted gross margin increased to 66% to 67% for 2023, with a gross margin of 67.8% in Q3, up over 1,200 basis points [85][93] - Adjusted operating margin was 12.2% and adjusted EBITDA was 19.1%, both exceeding expectations due to higher-than-anticipated revenue [88] Business Line Data and Key Metrics Changes - Drug Delivery revenue declined by 27%, slightly below guidance due to a lower forecast from partners [85] - Omnipod 5 adoption is driving significant growth, with expectations for US Omnipod revenue growth raised to 37% to 38% [91] Market Data and Key Metrics Changes - International Omnipod growth is expected to be between 9% to 10%, driven by Omnipod DASH adoption and new launches in the UK and Germany [92] - The company anticipates a favorable foreign currency impact of approximately 100 basis points on international growth [92] Company Strategy and Development Direction - The company is focused on expanding its market presence with Omnipod 5, which is positioned as a leading automated insulin delivery system [110] - There is a strong emphasis on innovation and global market opportunities, with plans for further international expansion [2][112] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth catalysts for 2024, including the integration of new technologies and continued strong demand for Omnipod products [63] - The company is optimistic about the potential for significant growth in the Type 2 diabetes market, particularly with the upcoming FDA filing for Omnipod 5 [60][70] Other Important Information - The company ended the quarter with $685 million in cash and $300 million available under its credit facility, providing flexibility for investments [89] - The Omnipod GO pilot is yielding positive insights into primary care engagement, which is crucial for Type 2 patient management [50][81] Q&A Session Summary Question: What are the growth contributions from upcoming developments? - Management highlighted excitement about growth catalysts, including iOS launch and international expansion, but did not provide specific guidance on contributions [5][6] Question: Were new patient starts a record worldwide? - New customer starts were strong but not a record, marking the second-highest quarter ever [11][12] Question: Update on the search for a new CFO? - The search is ongoing, with confidence in interim CFO Lauren Budden's capabilities [13][14] Question: Insights on margins for next year? - While not providing specific guidance, management is committed to expanding margins, with gross margins for 2023 expected to be between 66% to 67% [16][18] Question: Changes in marketing strategy with GLP adoption? - No changes in marketing strategy were reported, with continued success in customer conversions [21][22] Question: Timeline for returning to double-digit growth in international markets? - Management sees no barriers to growth in new markets, particularly with the launch of Omnipod 5 [27][28] Question: Competitive landscape for tubed and patch pumps? - The company remains confident in its competitive position, asserting that Omnipod 5 is superior to competitors' offerings [56][58] Question: Impact of the SECURE trial on commercial opportunities? - The SECURE trial is progressing well, with expectations to file for FDA approval in 2024 [60][70] Question: How is the company engaging with primary care physicians? - The Omnipod GO pilot is aimed at better understanding and engaging primary care practices [81][82]

Revenue Performance - Q3'233,4 • Total Company - $432.7, an increase of 27.0%, or 25.1% in constant currency • Total Omnipod - $422.0, an increase of 29.4%, or 27.5% in constant currency • U.S. Omnipod - $320.6, an increase of 34.6% • International Omnipod - $101.4, an increase of 15.2%, or 8.0% in constant currency Other Financial Highlights - Q3'23 • Gross margin of 67.8%, up 1,250 basis points, compared to gross margin of 55.3% in the prior year. Adjusted gross margin4 of 67.3%, up 120 basis points, excl ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of Registrant as specified in its charter) ___________________________________________ ...

Financial Performance - In Q2 2023, Insulet Corporation reported total revenue growth of 32%, exceeding expectations, with total Omnipod growth of 33% and U.S. growth of 41% [9][43] - The company raised its revenue growth outlook for the year, now expecting total Omnipod revenue growth of 25% to 28% and total company revenue growth of 22% to 25% [52][61] - Gross margin improved to 66.8%, up approximately 320 basis points year-over-year, driven by volume growth in the pharmacy channel and improved manufacturing efficiencies [47][49] Business Lines Performance - Omnipod 5 was responsible for nearly 95% of new customer starts in the U.S., indicating its strong market position [10][14] - International Omnipod revenue increased by 15%, driven by strong adoption of Omnipod DASH and timing of order and revenue recognition [46] - The U.S. pharmacy channel accounted for over 90% of total U.S. volume, enhancing customer access and affordability [45][18] Market Data - The company noted that the diabetes market remains vastly underpenetrated, with expectations that Omnipod will drive pump penetration to over 70% in the type 1 market from approximately 40% [17] - The U.S. market for type 2 diabetes patients needing intensive insulin therapy is estimated at 2.5 million, representing a significant opportunity for growth [78] Company Strategy and Industry Competition - Insulet is focused on expanding access to Omnipod 5 globally and leading in advanced innovation, with plans for a broader rollout in Europe in 2024 [38][42] - The company is actively defending its intellectual property and has taken legal action against competitors infringing on its patents [35][36] - The introduction of Omnipod GO aims to address barriers to insulin therapy, expanding the addressable market by at least 3 million people in the U.S. [29][30] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum, citing record new customer starts and strong demand for Omnipod 5 [64][68] - The company anticipates challenges in the second half of 2023 due to tougher comparisons but remains optimistic about maintaining growth rates [52][84] - Management highlighted the importance of ongoing innovation and clinical programs to drive long-term growth [28][33] Other Important Information - The company has submitted a 510(k) application to the FDA for the Omnipod 5 iOS app, which is highly requested by customers [32][119] - Insulet is advancing integration efforts with CGM partners to enhance the value proposition of Omnipod 5 [33] Q&A Session Summary Question: How to maintain momentum in Omnipod growth amid tough comparisons? - Management noted strong demand and record new customer starts for Omnipod 5, indicating continued growth potential [64][68] Question: Impact of GLP-1 drugs on type 2 diabetes market? - Management believes that GLP-1 drugs coexist with insulin therapies and that the market for intensive insulin therapy remains significant and largely untapped [71][78] Question: Insights on U.S. guidance and new patient additions? - Management provided insights on the impact of tough comparisons and emphasized the importance of new customer starts for sustaining growth [82][84] Question: International rollout of Omnipod 5 and growth expectations? - Management expressed excitement about the U.K. launch and noted that the growth dynamics in Europe differ from the U.S. due to contractual obligations [91][96] Question: Conversion of Omnipod Classic users to Omnipod 5? - Management confirmed that the conversion process is progressing well, with no significant increase in attrition rates observed [109][111]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of R ...

Christian D Podder Since 2020 Risks and uncertainties include, but are not limited to adverse changes in general economic conditions as well as risks associated with public health crises and pandemics, such as the COVID-19 global pandemic, government actions and restrictive measures implemented in response, supply chain disruptions, delays in clinical trials, and other impacts to the business, our customers, suppliers, and employees; dependence on a principal product platform; ability to maintain and grow o ...